<DOC>
	<DOCNO>NCT00427271</DOCNO>
	<brief_summary>Research design : randomize , double-blind , placebo-controlled crossover study evaluate putative interference low-dose aspirin ( 8 week ) enalapril antiproteinuric property microalbuminuric type 2 diabetes mellitus patient</brief_summary>
	<brief_title>Aspirin Enalapril Microalbuminuric Type 2 Diabetes Mellitus Patients</brief_title>
	<detailed_description>Research design : randomize , double-blind , placebo-controlled crossover study Patients : Microalbuminuric ( urinary albumin excretion [ UAE ] 30-300 mg/d ) type 2 diabetes mellitus patient without ischemic heart disease peptic ulcer Aim : To evaluate putative interference low-dose aspirin ( 300 mg/d ) 8 week ) enalapril antiproteinuric property microalbuminuric type 2 diabetes mellitus patient Study protocol : Crossover randomization 8 week enalapril 10 mg/d plus aspirin ( 300 mg/d ) plus placebo , 6-week washout period . Measurement UAE ( immunoturbidimetry ) glomerular filtration rate ( 51Cr-EDTA ) , blood pressure metabolic control baseline end period . Statistical analysis : Bland &amp; Altman analyse crossover trial .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<criteria>type 2 diabetes mellitus microalbuminuria ischemic heart disease peptic disease</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>aspirin</keyword>
	<keyword>enalapril</keyword>
	<keyword>microalbuminuria</keyword>
	<keyword>glomerular filtration rate</keyword>
</DOC>